| PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and … JE Logan, N Mostofizadeh, AJ Desai, E Von Euw, D Conklin, V Konkankit, ... Anticancer research 33 (8), 2997-3004, 2013 | 112 | 2013 |
| Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX … T Murakami, AS Singh, T Kiyuna, SM Dry, Y Li, AW James, K Igarashi, ... Oncotarget 7 (30), 47556, 2016 | 109 | 2016 |
| Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX … T Murakami, AS Singh, T Kiyuna, SM Dry, Y Li, AW James, K Igarashi, ... Oncotarget 7 (30), 47556, 2016 | 109 | 2016 |
| Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient … K Igarashi, K Kawaguchi, T Kiyuna, K Miyake, M Miyake, S Li, Q Han, ... Cell Cycle 17 (6), 801-809, 2018 | 63 | 2018 |
| Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of … K Igarashi, K Kawaguchi, S Li, Q Han, Y Tan, T Murakami, T Kiyuna, ... Cancer letters 417, 168-173, 2018 | 57 | 2018 |
| Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for … K Kawaguchi, Q Han, S Li, Y Tan, K Igarashi, T Kiyuna, K Miyake, ... Cell Cycle 17 (3), 356-361, 2018 | 53 | 2018 |
| Clinical and radiographic outcomes of concentrated bone marrow aspirate with allograft and demineralized bone matrix for posterolateral and interbody lumbar fusion in elderly … RM Ajiboye, JT Hamamoto, MA Eckardt, JC Wang European Spine Journal 24, 2567-2572, 2015 | 48 | 2015 |
| Giant cell tumor of bone: are we stratifying results appropriately? TJ Kremen Jr, NM Bernthal, MA Eckardt, JJ Eckardt Clinical Orthopaedics and Related Research® 470 (3), 677-683, 2012 | 45 | 2012 |
| Labeling the Stroma of a Patient‐Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft‐Tissue Sarcoma With Red Fluorescent Protein for Rapid Non … T Kiyuna, T Murakami, Y Tome, K Igarashi, K Kawaguchi, T Russell, ... Journal of cellular biochemistry 118 (2), 361-365, 2017 | 41 | 2017 |
| The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a … K Miyake, T Murakami, T Kiyuna, K Igarashi, K Kawaguchi, M Miyake, Y Li, ... Oncotarget 8 (61), 103129, 2017 | 39 | 2017 |
| Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma K Igarashi, K Kawaguchi, T Kiyuna, K Miyake, M Miyaki, N Yamamoto, ... Biochemical and biophysical research communications 506 (4), 912-917, 2018 | 35 | 2018 |
| Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models K Kawaguchi, Q Han, S Li, Y Tan, K Igarashi, K Miyake, T Kiyuna, ... Oncotarget 9 (13), 11119, 2018 | 32 | 2018 |
| Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model K Igarashi, K Kawaguchi, T Kiyuna, K Miyake, M Miyake, Y Li, SD Nelson, ... Oncotarget 9 (8), 7774, 2018 | 32* | 2018 |
| Growth of doxorubicin‐resistant undifferentiated spindle‐cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase K Igarashi, S Li, Q Han, Y Tan, K Kawaguchi, T Murakami, T Kiyuna, ... Journal of cellular biochemistry 119 (4), 3537-3544, 2018 | 31 | 2018 |
| Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse … K Igarashi, K Kawaguchi, T Kiyuna, K Miyake, M Miyake, AS Singh, ... Biochemical and biophysical research communications 497 (4), 1055-1061, 2018 | 30 | 2018 |
| Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma K Kawaguchi, T Higuchi, S Li, Q Han, Y Tan, K Igarashi, M Zhao, K Miyake, ... Biochemical and biophysical research communications 503 (4), 3086-3092, 2018 | 29 | 2018 |
| AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53 O Kalous, D Conklin, AJ Desai, J Dering, J Goldstein, C Ginther, ... Breast cancer research and treatment 141, 397-408, 2013 | 28 | 2013 |
| Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model K Igarashi, K Kawaguchi, S Li, Q Han, Y Tan, E Gainor, T Kiyuna, ... Oncotarget 9 (27), 19263, 2018 | 26 | 2018 |
| Image-guided percutaneous core needle biopsy of musculoskeletal tumors in children B Mitton, LL Seeger, MA Eckardt, K Motamedi, FC Eilber, SD Nelson, ... Journal of pediatric hematology/oncology 36 (5), 337-341, 2014 | 24 | 2014 |
| Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model K Igarashi, K Kawaguchi, T Kiyuna, K Miyake, M Miyake, Y Li, SD Nelson, ... Oncotarget 9 (8), 7774, 2018 | 23 | 2018 |
